Edgewise Therapeutics, Inc. Proceeds from Maturities, Prepayments and Calls of Held-to-maturity Securities
Edgewise Therapeutics, Inc. (EWTX) reported Proceeds from Maturities, Prepayments and Calls of Held-to-maturity Securities of $217.69 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Investing Activities
us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities · last filed 2026-08-06
- Edgewise Therapeutics, Inc. proceeds from maturities, prepayments and calls of held-to-maturity securities for the quarter ending 2026-06-30 was $108.81M, a 39.50% increase year-over-year.
- Edgewise Therapeutics, Inc. proceeds from maturities, prepayments and calls of held-to-maturity securities for the quarter ending 2026-03-31 was $108.88M, a 27.95% decline year-over-year.
- Edgewise Therapeutics, Inc. proceeds from maturities, prepayments and calls of held-to-maturity securities for the quarter ending 2025-12-31 was $108.19M, a 33.07% increase year-over-year.
- Edgewise Therapeutics, Inc. proceeds from maturities, prepayments and calls of held-to-maturity securities for the quarter ending 2025-09-30 was $90.00M.
- Edgewise Therapeutics, Inc. proceeds from maturities, prepayments and calls of held-to-maturity securities for fiscal 2025 was $427.31M, a 53.75% increase from fiscal 2024.
- Edgewise Therapeutics, Inc. proceeds from maturities, prepayments and calls of held-to-maturity securities for fiscal 2024 was $277.92M, a 19.30% decline from fiscal 2023.
- Edgewise Therapeutics, Inc. proceeds from maturities, prepayments and calls of held-to-maturity securities for fiscal 2023 was $344.38M.
| Period end | Proceeds from Maturities, Prepayments and Calls of Held-to-maturity Securities 3 month | Proceeds from Maturities, Prepayments and Calls of Held-to-maturity Securities 6 month | Proceeds from Maturities, Prepayments and Calls of Held-to-maturity Securities 9 month | Proceeds from Maturities, Prepayments and Calls of Held-to-maturity Securities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $108.81M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $217.69M 10-Q · filed 2026-08-06 | $325.87M derived: sum of 3 quarters · filed 2026-08-06 | $415.88M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $108.88M 10-Q · filed 2026-05-07 | $217.07M derived: sum of 2 quarters · filed 2026-05-07 | $307.07M derived: sum of 3 quarters · filed 2026-05-07 | $385.06M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $108.19M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $198.19M derived: sum of 2 quarters · filed 2026-02-26 | $276.19M derived: sum of 3 quarters · filed 2026-08-06 | $427.31M 10-K · filed 2026-02-26 |
| 2025-09-30 | $90.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $168.00M derived: sum of 2 quarters · filed 2026-08-06 | $319.12M 10-Q · filed 2025-11-06 | $400.42M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $78.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $229.12M 10-Q · filed 2026-08-06 | $310.42M derived: sum of 3 quarters · filed 2026-08-06 | |
| 2025-03-31 | $151.12M 10-Q · filed 2026-05-07 | $232.42M derived: sum of 2 quarters · filed 2026-05-07 | ||
| 2024-12-31 | $81.30M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $277.92M 10-K · filed 2026-02-26 | ||
| 2024-09-30 | $196.62M 10-Q · filed 2025-11-06 | |||
| 2023-12-31 | $344.38M 10-K · filed 2026-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 |